drugset / Trial / NCT03382886
Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, phase I study to test for maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of the combination of nivolumab and bevacizumab. The study will use a 3+3 phase I study design using a fixed dose of nivolumab (240mg) and escalating doses of bevacizumab (1-10mg).
Timeline
- Start
- 2018-04-11
- Primary completion
- 2018-07-26
- Completion
- 2019-07-02
Outcome
Outcome not reported
Stopped (Enrollment): “PI decided to terminate due to low/slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |